Clinical Trial

Small Intestinal Bacterial Overgrowth (SIBO) in Pancreatic Adenocarcinoma (PDAC)

Study acronym: SIBO in PDAC
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated May 23, 2025 (before its estimated April 14, 2026 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this study is to prospectively analyze the prevalence of SIBO in patients with Pancreatic adenocarcinoma (PDAC) and understand its association with weight loss and pancreatic resection status. Each patient will be tested for SIBO using Lactulose Hydrogen Breath Test. 100 patients with diagnosed pancreatic adenocarcinoma and clinically diagnosed weight loss will be enrolled in this study.
Trial Details
NCT Number NCT06988150
Lead Sponsor Cedars-Sinai Medical Center
Conditions Pancreatic Adenocarcinoma, Weight Loss
Enrollment 100 participants
Start Date 2025-04-14
Primary Completion 2026-04-14 (estimated)
Study Completion 2026-04-14 (estimated)
Updated on ClinicalTrials.gov 2025-05-23